LipoSurg ARTIST
NOUVAG AG · Decision date Sep 5, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for LipoSurg ARTIST, a suction lipoplasty removal system submitted by NOUVAG AG of Goldach, Switzerland, under 510(k) number K254135. The decision date is 09/05/2026; the application was received 12/22/2025 and handled as a traditional 510(k) reviewed by FDA rather than a third party. SESE means the device was cleared as substantially equivalent to a predicate, not approved through the PMA pathway.
The record lists regulation number 878.5040, product code QPB, and the General & Plastic Surgery specialty and review panel. The submission was not a combination product, and no predetermined change control plan was authorized. The public record does not include the predicate device, the specific components or changes described in the submission, or the indications for use; those details would sit in the underlying FDA documents rather than this summary page.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 5, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254135
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- NOUVAG AG
- Product code
- QPB
- Decision code
- SESE
- Decision date
- Sep 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Suction, Lipoplasty For Removal.
FDA decision timeline
K254135 received
Application receipt date recorded by FDA.
K254135 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
NOUVAG AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Sankt Gallen
Sources and methodology
- Original FDA record: K254135
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records